Susquehanna International Group, LLP Kinnate Biopharma Inc. Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	BUY	$2.24 - $2.66 $492,692 - $585,072	219,952 Added 71.86%	526,021 $1.4 Million
Q4 2023 Feb 14, 2024	BUY	$1.07 - $2.5 $171,832 - $401,477	160,591 Added 110.39%	306,069 $725,000
Q3 2023 Nov 14, 2023	BUY	$1.38 - $3.31 $534 - $1,280	387 Added 0.27%	145,478 $203,000
Q2 2023 Aug 11, 2023	BUY	$2.33 - $6.84 $244,430 - $717,557	104,906 Added 261.06%	145,091 $439,000
Q1 2023 May 16, 2023	BUY	$3.46 - $7.98 $139,040 - $320,676	40,185 New	40,185 $251,000
Q2 2022 Aug 15, 2022	BUY	$7.43 - $13.0 $3,640 - $6,370	490 Added 4.21%	12,130 $153,000
Q4 2021 Feb 14, 2022	BUY	$16.5 - $25.48 $192,060 - $296,587	11,640 New	11,640 $206,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.